Search
Pramiracetam
go.drugbank.com/drugs/DB13247ApprovedPramiracetam has been previously approved in some eastern European countries under the brand names Pramistar, Neupramir, and Remen. … Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive functioning post-electroconvulsive therapy in severe depression [L5470].
Romlusevimab
go.drugbank.com/drugs/DB16494InvestigationalRomlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.
Queuine
go.drugbank.com/drugs/DB14732ExperimentalNutraceuticalBacteria possess the exclusive ability to synthesize queuine, which is then salvaged and passed on to plants and animals. … Quantities of queuine have been found in tomatoes, wheat, coconut water, and milk from humans, cows, and goats. Humans salvage and recover queuine from either ingested food or the gut flora.
Progabide
go.drugbank.com/drugs/DB00837ExperimentalProgabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. … In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these conditions is not fully elucidated
MN-246
go.drugbank.com/drugs/DB05981ExperimentalMN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.
Alimemazine
go.drugbank.com/drugs/DB01246ApprovedVet approvedWithdrawnA phenothiazine derivative that is used as an antipruritic.
XmAb 2513
go.drugbank.com/drugs/DB06324InvestigationalXmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types.
MPI-674
go.drugbank.com/drugs/DB05749ExperimentalMPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. … AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.